13.13
price down icon0.51%   -0.065
 
loading
Viatris Inc stock is traded at $13.13, with a volume of 1.33M. It is down -0.51% in the last 24 hours and up +13.02% over the past month. Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$13.20
Open:
$13.21
24h Volume:
1.33M
Relative Volume:
0.18
Market Cap:
$15.64B
Revenue:
$15.05B
Net Income/Loss:
$-883.30M
P/E Ratio:
8.585
EPS:
1.53
Net Cash Flow:
$1.89B
1W Performance:
+0.40%
1M Performance:
+13.02%
6M Performance:
+24.12%
1Y Performance:
+40.15%
1-Day Range:
Value
$13.03
$13.23
1-Week Range:
Value
$13.01
$13.24
52-Week Range:
Value
$9.305
$13.62

Viatris Inc Stock (VTRS) Company Profile

Name
Name
Viatris Inc
Name
Phone
(724) 514-1465
Name
Address
1000 MYLAN BOULEVARD, CANONSBURG
Name
Employee
38,000
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
VTRS's Discussions on Twitter

Compare VTRS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
13.13 15.64B 15.05B -883.30M 1.89B -0.74
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
180.79 79.24B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.92 43.58B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.735 43.54B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.43 19.62B 16.77B -959.00M 1.37B -0.85

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-19-24 Resumed Jefferies Buy
Oct-23-23 Downgrade BofA Securities Neutral → Underperform
Jun-23-23 Downgrade Barclays Equal Weight → Underweight
Apr-24-23 Downgrade Barclays Overweight → Equal Weight
Feb-17-23 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-27-23 Upgrade Jefferies Hold → Buy
Nov-10-22 Upgrade UBS Sell → Neutral
Nov-08-22 Upgrade Piper Sandler Underweight → Neutral
Oct-21-22 Resumed Jefferies Hold
Jun-14-22 Initiated UBS Sell
May-10-22 Downgrade Piper Sandler Neutral → Underweight
Mar-01-22 Downgrade BofA Securities Buy → Neutral
Mar-01-22 Downgrade Raymond James Outperform → Mkt Perform
Jun-15-21 Initiated Citigroup Neutral
Apr-07-21 Resumed RBC Capital Mkts Outperform
Mar-08-21 Downgrade Goldman Buy → Neutral
Mar-02-21 Downgrade JP Morgan Overweight → Neutral
Feb-26-21 Downgrade Wolfe Research Outperform → Peer Perform
Jan-05-21 Initiated Argus Hold
Dec-14-20 Initiated Bernstein Mkt Perform
View All

Viatris Inc Stock (VTRS) Latest News

pulisher
Dec 02, 2024

Anti Depression Drugs Market is expected to reach US$ 22.10 - openPR

Dec 02, 2024
pulisher
Dec 02, 2024

Naloxone Market Growth in Future Scope 2024-2031 | Akorn, Inc, - openPR

Dec 02, 2024
pulisher
Nov 29, 2024

Viatris Says Goodbye To Another Generics Asset - Citeline

Nov 29, 2024
pulisher
Nov 27, 2024

2 Generic Drug Stocks Ready to Surge in 2025 - MarketBeat

Nov 27, 2024
pulisher
Nov 26, 2024

Hypopituitarism Treatment Market to Witness Huge Growth - openPR

Nov 26, 2024
pulisher
Nov 26, 2024

Hypovolemic Shock Market Growth Analysis: Industry Expansion - openPR

Nov 26, 2024
pulisher
Nov 25, 2024

UK CMA fines Viatris for breaching order during Theramex deal probe - World Pharmaceutical Frontiers

Nov 25, 2024
pulisher
Nov 24, 2024

Viatris fined in Morocco over merger notification, sources say - MSN

Nov 24, 2024
pulisher
Nov 24, 2024

Vitaris fined in Morocco over merger notification, sources say - MSN

Nov 24, 2024
pulisher
Nov 23, 2024

Morocco fines Viatris 7.58 million dirhams over Mylan-Pfizer merger - MSN

Nov 23, 2024
pulisher
Nov 22, 2024

Viatris Reports Third Quarter Financial Results for 2024 - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe - Reuters.com

Nov 22, 2024
pulisher
Nov 22, 2024

Viatris Fined £1.5M For Failing To Comply With CMA Order - Law360

Nov 22, 2024
pulisher
Nov 22, 2024

Viatris fined £1.5M for failure to comply with CMA order - MSN

Nov 22, 2024
pulisher
Nov 22, 2024

Viatris fined £1.5M for failure to comply with CMA order (NASDAQ:VTRS) - Seeking Alpha

Nov 22, 2024
pulisher
Nov 22, 2024

UK watchdog fines Viatris $1.9 million over rule breach in Theramex probe - Marketscreener.com

Nov 22, 2024
pulisher
Nov 22, 2024

Viatris Fined £1.5M for CMA Order Breach - Mirage News

Nov 22, 2024
pulisher
Nov 22, 2024

Viatris fined £1.5m for failure to comply with CMA order - GOV.UK

Nov 22, 2024
pulisher
Nov 22, 2024

Ampicillin Market to Continue Impressive Measured Growth - openPR

Nov 22, 2024
pulisher
Nov 21, 2024

Australia Passes Strict Social Media Ban for Under-16s - PYMNTS.com

Nov 21, 2024
pulisher
Nov 21, 2024

Viatris fined in Morocco over merger notification, sources say By Reuters - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

Viatris Fined in Morocco Over Merger Notification, Sources Say - U.S News & World Report Money

Nov 21, 2024
pulisher
Nov 21, 2024

Psoriasis Biosimilars Market Key Players AnalysisMerck KGaA, - openPR

Nov 21, 2024
pulisher
Nov 21, 2024

United States Active Pharmaceutical Ingredients (API) Market May See a Big Move | Merck, Novartis, Viatris, Lupin - openPR

Nov 21, 2024
pulisher
Nov 20, 2024

Ex-Dividend Reminder: NextEra Energy, CRH and Viatris - Nasdaq

Nov 20, 2024
pulisher
Nov 20, 2024

Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth!Major Drivers - Smartkarma

Nov 20, 2024
pulisher
Nov 19, 2024

Viatris Inc. Rings the Closing Bell - Nasdaq

Nov 19, 2024
pulisher
Nov 19, 2024

Catecholamines Drugs Market Specialized New Report, See Growth - openPR

Nov 19, 2024
pulisher
Nov 19, 2024

Cerebral Palsy Treatment Market Growth Overview: - openPR

Nov 19, 2024
pulisher
Nov 19, 2024

Transdermal Skin Patches Market Overall Study Report 2024-2031 - openPR

Nov 19, 2024
pulisher
Nov 18, 2024

Safecor Health Acquires Viatris’ U.S. Unit-Dose Packaging Business - citybiz

Nov 18, 2024
pulisher
Nov 18, 2024

Safecor Health Announces Acquisition of Viatris' U.S. Unit-Dose Packaging Business - PR Newswire

Nov 18, 2024
pulisher
Nov 18, 2024

VSCP-backed Safecor Health picks up Viatris Inc’s US unit-dose packaging business - PE Hub

Nov 18, 2024
pulisher
Nov 15, 2024

Influenza Vaccines Industry May See a Big Move | BIKEN, Viatris, Sinovac Biotech - openPR

Nov 15, 2024
pulisher
Nov 13, 2024

Chris Davis's Strategic Acquisition of Viatris Inc Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Viatris's SWOT analysis: generic drug maker's stock faces growth hurdles - Investing.com

Nov 13, 2024
pulisher
Nov 12, 2024

Viatris Inc's chief accounting officer sells $346,686 in stock - Investing.com India

Nov 12, 2024

Viatris Inc Stock (VTRS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$126.69
price up icon 0.53%
$17.42
price up icon 4.59%
$61.94
price up icon 0.86%
$85.50
price down icon 0.70%
$12.48
price down icon 7.42%
Cap:     |  Volume (24h):